Evidence map›Paper›PMID 41201647›Full record

ArticleEJNMMI physics2025

Radiation exposure to families of patients following administration of

D Levart, S Wicks, N Heraghty, E Kalogianni, N Mulholland

Abstract read
In one paragraph

Article in EJNMMI physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

D LevartKing's College Hospital NHS Foundation Trust, London, UK. Danielle.levart@nhs.net.ORCID http://orcid.org/0000-0001-5893-0700
S WicksLeeds Teaching Hospitals NHS Trust, Leeds, UK.
N HeraghtyKing's College Hospital NHS Foundation Trust, London, UK.
E KalogianniKing's College Hospital NHS Foundation Trust, London, UK.
N MulhollandKing's College Hospital NHS Foundation Trust, London, UK.

Funding

Novartis Pharmaceuticals UK Limited Novartis Pharmaceuticals UK Limited
6 · The paper itself

Abstract

backgroundThe administration of

resultsParticipating family members (n = 12) received a median of 0.038 mSv effective dose over 4 weeks from patients administered a median of 7515 MBq

conclusionImplementing standardised contact restrictions for patients and their family members following

Indexed as

177Lu-DOTATATERadiation ProtectionRadionuclide Therapy

Identifiers

PMID41201647
PMCPMC12595148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.